NCT02626507
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions: Patients with IBC; Patients with a high tumor burden which includes more than one metastatic site in the liver or lung, and more than three metastatic sites in the bone; Active central nervous system (CNS), epidural tumor or metastasis, or brain metastasis
https://ClinicalTrials.gov/show/NCT02626507